WASHINGTON, April 19 (Reuters) - Longer-term results from a head-to-head trial of two drugs that prevent breast cancer shows that tamoxifen works better than rival Eli Lilly and Co's Evista, but with ...
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables PURPOSE: To identify predictors of ...
An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback